Glucagon-like peptide-1
GCGpeptideGLP-1 exerts anti-thrombotic and anti-inflammatory effects, reducing platelet aggregation and endothelial activation in MI pathogenesis.
Pathway placement
Cascade stepPlatelet adhesion & activation
Confidencemedium
RationaleAnti-thrombotic and anti-inflammatory; suppresses thrombus growth and platelet aggregation.
Also acts inVascular inflammation, Endothelial activation/erosion
Druggability
DruggableYes
Known drugs / candidates0
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000115263
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Plasma (EDTA; peptidase-labile — chilled + protease inhibitor)
Collection tube
K2-EDTA, chilled plastic (lavender-top) · Serum separator (gold/red-top, SST)
Method / principle
Competitive/sandwich immunoassay or LC-MS/MS
Reagent / substrate
Anti-peptide antibody; or isotope-labeled internal standard (MS)
Platform
Immunoassay / LC-MS/MS
Turnaround · availability
Send-out / research · Research-grade
Human genetic evidence
0.014
Open Targets association (STEMI)
Literature evidence(3)
- Native, Intact Glucagon-Like Peptide 1 Is a Natural Suppressor of Thrombus Growth Under Physiological Flow Conditions.Arteriosclerosis, thrombosis, and vascular biology · 2020 · PMID 31893947 · doi
- Glucagon-like peptide-1 receptor signalling reduces microvascular thrombosis, nitro-oxidative stress and platelet activation in endotoxaemic mice.British journal of pharmacology · 2016 · PMID 27435156 · doi
- CARDIOVASCULAR OUTCOME TRIALS OF THE INCRETIN-BASED THERAPIES: WHAT DO WE KNOW SO FAR?Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2016 · PMID 27819769 · doi